Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PTEN inact mut XL147 prostate adenocarcinoma sensitive detail...
PTEN inact mut Paclitaxel + XL147 prostate adenocarcinoma sensitive detail...
Unknown unknown NSC23766 prostate adenocarcinoma not applicable detail...
Unknown unknown ONC201 prostate adenocarcinoma not applicable detail...
ATM L1449* Olaparib prostate adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00002651 Phase III Bicalutamide Goserelin Hormone Therapy in Treating Men With Stage IV Prostate Cancer Completed
NCT00223665 Phase II Leuprolide Flutamide Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy Completed
NCT00536991 Phase Ib/II Prednisone calcitriol Ketoconazole Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer Terminated
NCT00541047 Phase III Leuprolide Goserelin Bicalutamide Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS) Active, not recruiting
NCT00589420 Phase II Docetaxel + Sorafenib Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy Completed
NCT00859781 Phase II Prednisone Ketoconazole 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Recruiting
NCT00936390 Phase III Flutamide Goserelin Leuprolide Triptorelin Bicalutamide Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Active, not recruiting
NCT01174199 Phase I Temsirolimus + Vorinostat Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer Terminated
NCT01313559 Phase II Everolimus + Pasireotide Pasireotide Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer Terminated
NCT01342367 Phase I Bicalutamide Dutasteride Finasteride Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer Active, not recruiting
NCT01409200 Phase II Axitinib Neoadjuvant Axitinib in Prostate Cancer Active, not recruiting
NCT01420250 Phase I Bicalutamide Cabazitaxel Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer Active, not recruiting
NCT01485861 Phase II GDC-0980 Abiraterone Ipatasertib Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy Active, not recruiting
NCT01498978 Phase II Ipilimumab Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Active, not recruiting
NCT01503229 Phase II Prednisone Abiraterone Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Active, not recruiting
NCT01513733 Phase I Tasquinimod Cabazitaxel The CATCH Prostate Cancer Trial Cabazitaxel And Tasquinimod in Men With Prostate Cancer Completed
NCT01548807 Phase I Everolimus Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy Completed
NCT01560923 Phase II Sipuleucel-T Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer Completed
NCT01619813 Phase II Docetaxel + Prednisone Reolysin Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer Completed
NCT01630590 Phase II Cabozantinib Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer Active, not recruiting
NCT01681433 Phase II Prednisone Abiraterone OGX-427 OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone Terminated
NCT01688492 Phase Ib/II Abiraterone + Prednisone Ipilimumab Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer Active, not recruiting
NCT01695473 Phase II Buparlisib Neoadjuvant BKM120 in High-risk Prostate Cancer Completed
NCT01703065 Phase I Cabozantinib Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer Terminated
NCT01706458 Phase II pTVG-HP plasmid DNA vaccine Sipuleucel-T Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer Active, not recruiting
NCT01709734 Phase II galeterone A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Completed
NCT01786265 Phase II Goserelin Degarelix Abiraterone Prednisone Leuprolide Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone Active, not recruiting
NCT01787331 Phase II Itraconazole A Phase II Study of Itraconazole in Biochemical Relapse Completed
NCT01790126 Phase II Apalutamide The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer Active, not recruiting
NCT01804465 Phase II Ipilimumab A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer Recruiting
NCT01807065 Phase II Sipuleucel-T Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Active, not recruiting
NCT01812668 Phase I Cabozantinib Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Active, not recruiting
NCT01832259 Phase II Pazopanib A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection Completed
NCT01845792 Phase II Cabazitaxel Abiraterone Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer Terminated
NCT01848067 Phase Ib/II Abiraterone Prednisone Alisertib Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer Completed
NCT01885949 Phase II Enzalutamide + Tivozanib Tivozanib + Enzalutamide in Adv Prostate Cancer Active, not recruiting
NCT01927627 Phase II Enzalutamide Enzalutamide in Patients With High-risk Prostate Cancer Completed
NCT01940276 Phase II Abiraterone + Prednisone Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer Active, not recruiting
NCT01942837 Phase II Enzalutamide Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling Active, not recruiting
NCT01946204 Phase III Apalutamide A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer Active, not recruiting
NCT01949337 Phase III Abiraterone Prednisone Enzalutamide Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Active, not recruiting
NCT01961843 Phase I Prednisone Abiraterone Abiraterone Acetate for Castrate Resistant Prostate Cancer Active, not recruiting
NCT01977651 FDA approved Enzalutamide A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide Completed
NCT01996696 Phase II Metformin A Study With or Without Metformin to Determine if Metformin Can Prevent Weight Gain and Other Problems (i.e. Diabetes, Increased Cholesterol, Etc.) That Can Arise From the Use of Hormonal Therapy in Combination With Radiation Therapy When Treating Aggressive Localized Prostate Cancer. Recruiting
NCT02003924 Phase III Enzalutamide Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Active, not recruiting
NCT02023463 Phase I Goserelin Enzalutamide Leuprolide Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer Active, not recruiting
NCT02025010 Phase II Abiraterone Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates. Active, not recruiting
NCT02034552 Phase II Prednisone Radium Ra 223 dichloride Enzalutamide Abiraterone A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) Completed
NCT02036918 Phase I Sipuleucel-T Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer Completed
NCT02043678 Phase III Prednisone Abiraterone Radium Ra 223 dichloride Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms Active, not recruiting
NCT02057939 Phase II Enzalutamide Leuprolide Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) Completed
NCT02058706 Phase II Goserelin Bicalutamide Enzalutamide Leuprolide LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer Active, not recruiting
NCT02064036 Phase I Bicalutamide Goserelin Leuprolide Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate Recruiting
NCT02064582 Phase II Leuprolide Enzalutamide Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer Active, not recruiting
NCT02090114 Phase II Testosterone Abiraterone Enzalutamide RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study) Recruiting
NCT02106507 Phase I Apalutamide + Everolimus ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate Active, not recruiting
NCT02111187 Phase I Sonidegib A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer Completed
NCT02123758 Phase I Abiraterone + Apalutamide + Prednisone A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting
NCT02125084 Phase I Enzalutamide + Everolimus Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer Active, not recruiting
NCT02125357 Phase II Enzalutamide Abiraterone Sequencing Abiraterone and Enzalutamide in mCRPC Active, not recruiting
NCT02146833 Phase II Selinexor Study of Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma Terminated
NCT02176161 Phase II Metformin Metformin Prostate Cancer Adjuvant Trial Recruiting
NCT02182622 Phase I Docetaxel Sonidegib LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel Withdrawn
NCT02199197 Phase II Enzalutamide Radium Ra 223 With Enzalutamide in Men With Metastatic Castration Refractory Prostate Cancer Active, not recruiting
NCT02200614 Phase III Darolutamide Efficacy and Safety Study of ODM-201 in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer Active, not recruiting
NCT02203695 Phase II Enzalutamide Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy Recruiting
NCT02204072 Phase I Enzalutamide Xentuzumab BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) Active, not recruiting
NCT02207504 Phase I Crizotinib + Enzalutamide Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Active, not recruiting
NCT02213107 Phase II Dutasteride + Enzalutamide Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer. Active, not recruiting
NCT02215096 Phase I Enzalutamide GSK2636771 Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer Recruiting
NCT02215161 Phase II Selinexor Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide Terminated
NCT02217566 Phase II Abiraterone Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy Completed
NCT02217709 Phase II Phenelzine Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer Recruiting
NCT02254785 Phase II Abiraterone Enzalutamide Cabazitaxel Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer Active, not recruiting
NCT02256111 Phase II Enzalutamide EXTEND Exercise Trial Completed
NCT02257736 Phase III Abiraterone + Apalutamide Abiraterone An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Active, not recruiting
NCT02262910 Phase I MOR209/ES414 Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer Active, not recruiting
NCT02268175 Phase II Enzalutamide Abiraterone Prednisone Leuprolide Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate Active, not recruiting
NCT02284971 Phase I Varlilumab Pilot Study of SBRT and CDX-1127 in Prostate Cancer (Prostate-04) Terminated
NCT02286921 Phase II Enzalutamide Testosterone Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance Active, not recruiting
NCT02319837 Phase III Leuprolide Enzalutamide Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) Active, not recruiting
NCT02346253 Phase Ib/II Leuprolide Triptorelin Degarelix Bicalutamide Goserelin High-Dose Brachytherapy in Treating Patients With Prostate Cancer Recruiting
NCT02349139 Phase Ib/II ASN001 Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer Terminated
NCT02353715 Phase I Abiraterone Enzalutamide Sipuleucel-T Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing Completed
NCT02376166 Phase I Metformin Metformin for Rising PSA Remote Trial Completed
NCT02379390 Phase II Prednisone Abiraterone Enzalutamide Cabazitaxel Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB) Terminated
NCT02381236 Phase II mipsagargin G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer Completed
NCT02384382 Phase II Enzalutamide A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) Completed
NCT02396368 Phase I Tasquinimod Radium Ra 223 dichloride A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer Withdrawn
NCT02407054 Phase II Enzalutamide LY3023414 A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Active, not recruiting
NCT02411786 Phase I pTVG-AR Sargramostim A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF Active, not recruiting
NCT02415621 Phase I Abiraterone Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer Recruiting
NCT02441517 FDA approved Enzalutamide A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel Treatment in Patients Who Have Previously Received Enzalutamide Terminated
NCT02446405 Phase III Enzalutamide Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer Active, not recruiting
NCT02446444 Phase III Enzalutamide Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer Active, not recruiting
NCT02463799 Phase II Radium Ra 223 dichloride Sipuleucel-T Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC Active, not recruiting
NCT02472275 Phase I Leuprolide Pexidartinib Goserelin Degarelix PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer Suspended
NCT02489318 Phase III Apalutamide A Phase 3 Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC Active, not recruiting
NCT02491411 Phase I Enzalutamide Dexamethasone Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel Terminated
NCT02494713 Phase II Degarelix Estramustine Docetaxel Doxorubicin Ketoconazole Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer Terminated
NCT02497638 Phase II Atorvastatin + Metformin LIpitor and biGuanide to Androgen Delay Trial Not yet recruiting
NCT02499835 Phase Ib/II Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer Recruiting
NCT02500901 Phase I Niraparib Enzalutamide Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) Terminated
NCT02506114 Phase II PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM Ipilimumab Ipilimumab + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer Recruiting
NCT02508636 Phase II Enzalutamide + Leuprolide Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Active, not recruiting
NCT02532114 Phase I Enzalutamide Niclosamide Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer Completed
NCT02543255 Phase II Cabazitaxel Abiraterone + Leuprolide + Prednisone Pegfilgrastim Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) Recruiting
NCT02560051 Phase II Degarelix Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer Terminated
NCT02578797 Phase I Apalutamide A JNJ-56021927 (ARN-509) QT/QTc Study Active, not recruiting
NCT02582749 Phase II Bicalutamide + Radium Ra 223 dichloride Bicalutamide Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases Terminated
NCT02601014 Phase II Ipilimumab + Nivolumab Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 Recruiting
NCT02606123 Phase Ib/II EPI-506 Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer Terminated
NCT02625857 Phase I JNJ-64041809 Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer Completed
NCT02643667 Phase Ib/II Ibrutinib A Study of Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer Recruiting
NCT02677896 Phase III Enzalutamide A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Active, not recruiting
NCT02685267 Phase II Docetaxel + Enzalutamide + Prednisone Docetaxel + Prednisone Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza) Active, not recruiting
NCT02685397 Phase II Enzalutamide Triptorelin Goserelin Leuprolide Management of Castration-Resistant Prostate Cancer With Oligometastases Recruiting
NCT02703623 Phase II Ipilimumab Abiraterone + Apalutamide + Prednisone Cabazitaxel + Carboplatin A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO) Recruiting
NCT02716974 Phase I Bicalutamide + Docetaxel + Leuprolide A Study of Definitive Therapy to Treat Prostate Cancer Recruiting
NCT02721979 Phase II Apalutamide ARN-509 in Treating Patients With Prostate Cancer Who Are in Active Surveillance Recruiting
NCT02758132 Phase I Abiraterone + Denosumab + Enzalutamide + Prednisone Denosumab + Enzalutamide Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases Terminated
NCT02768363 Phase II AdV-tk + Valacyclovir Valacyclovir Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) Active, not recruiting
NCT02770391 Phase II Apalutamide + Leuprolide ARN-509 and Leuprolide in Intermediate and High-risk Prostate Cancer Recruiting
NCT02772588 Phase II Abiraterone + Apalutamide + Leuprolide AASUR in High Risk Prostate Cancer Recruiting
NCT02787005 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199) Active, not recruiting
NCT02788773 Phase II Durvalumab + Tremelimumab Durvalumab Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer Recruiting
NCT02793219 Phase II Docetaxel + Sipuleucel-T Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer Withdrawn
NCT02793765 Phase II Docetaxel + Sipuleucel-T Docetaxel Followed by Provenge in Metastatic Prostate Cancer Withdrawn
NCT02799602 Phase III Darolutamide Darolutamide + Docetaxel ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS) Active, not recruiting
NCT02799745 Phase II Enzalutamide A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) (ENACT) Active, not recruiting
NCT02811809 Phase II Leuprolide Apalutamide + Leuprolide Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer Not yet recruiting
NCT02814669 Phase I Atezolizumab + Radium Ra 223 dichloride Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor Active, not recruiting
NCT02849990 Phase II Abiraterone + Apalutamide + Degarelix + Indomethacin + Prednisone Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients With Localized Prostate Cancer Before Surgery Active, not recruiting
NCT02861573 Phase I Dexamethasone + Docetaxel + Pembrolizumab + Prednisone Olaparib + Pembrolizumab Enzalutamide + Pembrolizumab Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting
NCT02893917 Phase II Cediranib + Olaparib Olaparib Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Active, not recruiting
NCT02903160 Phase II Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) Recruiting
NCT02903368 Phase II Abiraterone + Leuprolide + Prednisone Abiraterone + Apalutamide + Leuprolide + Prednisone Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy Active, not recruiting
NCT02905318 Phase II Palbociclib Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting
NCT02906605 Phase II Apalutamide Apalutamide + JNJ-64041809 A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer Withdrawn
NCT02913196 Phase I Abiraterone + Apalutamide + Docetaxel + Prednisone Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC Recruiting
NCT02923180 Phase I MGA271 Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer Recruiting
NCT02949284 Phase II Apalutamide Abiraterone + Apalutamide + Prednisone Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery Recruiting
NCT02952534 Phase II Rucaparib A Study of Rucaparib in Patients With MetA Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2) Recruiting
NCT02987829 Phase Ib/II TRC253 A Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients Recruiting
NCT02991911 Phase I Enzalutamide + MEDI3726 MEDI3726 A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer Active, not recruiting
NCT02995330 Phase I Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Tacrolimus + Testosterone cypionate Cyclophosphamide + Fludarabine Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer Recruiting
NCT03007732 Phase II Pembrolizumab + SD-101 Pembrolizumab Pembrolizumab in Combination With Intratumoral SD-101 Therapy Recruiting
NCT03009981 Phase III Abiraterone + Apalutamide + Degarelix + Prednisone Apalutamide + Degarelix Degarelix A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer Recruiting
NCT03012321 Phase II Abiraterone + Olaparib + Prednisone Abiraterone + Prednisone Olaparib Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects Recruiting
NCT03016312 Phase III Atezolizumab + Enzalutamide Enzalutamide IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen Active, not recruiting
NCT03024216 Phase I Atezolizumab + Sipuleucel-T Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer Recruiting
NCT03030885 Phase I 131I-MIP-1095 Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Completed
NCT03042468 Phase I 177Lu-PSMA-617 Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC Recruiting
NCT03043807 Phase II Bicalutamide + Docetaxel + Leuprolide A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy Recruiting
NCT03047135 Phase II Olaparib Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis Recruiting
NCT03070886 Phase III Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery Recruiting
NCT03072238 Phase III Abiraterone Abiraterone + Ipatasertib Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer Recruiting
NCT03076203 Phase I Niraparib + Radium Ra 223 dichloride Radium Ra 223 Dichloride and Niraparib in Treating Patients With Hormone- Resistant Prostate Cancer Metastatic to the Bone Recruiting
NCT03085095 Phase III Relugolix Leuprolide A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO) Recruiting
NCT03093272 Phase II Leuprolide Prednisone Apalutamide + Docetaxel A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer Recruiting
NCT03093428 Phase II Pembrolizumab + Radium Ra 223 dichloride Radium Ra 223 dichloride Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC Recruiting
NCT03098836 Phase II Abiraterone + Apalutamide + Prednisone Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer Recruiting
NCT03147196 Phase II Bicalutamide + Raloxifene Raloxifene Bicalutamide Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery Withdrawn
NCT03148795 Phase II Talazoparib A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Recruiting
NCT03150056 Phase I Abiraterone + GSK525762 Enzalutamide + GSK525762 Prednisone Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer Active, not recruiting
NCT03177460 Phase I Daratumumab JNJ-40346527 Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer Recruiting
NCT03204812 Phase II Durvalumab + Tremelimumab Tremelimumab + Durvalumab Chemotherapy Naive CRPC Active, not recruiting
NCT03248570 Phase II Pembrolizumab Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects Recruiting
NCT03279250 Phase II Goserelin Triptorelin Abiraterone + Apalutamide + Prednisone Leuprolide Apalutamide Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence Active, not recruiting
NCT03298087 Phase II Abiraterone + Apalutamide + Leuprolide Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer Recruiting
NCT03300505 Phase Ib/II AZD5312 + Enzalutamide ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer Recruiting
NCT03317392 Phase Ib/II Olaparib Olaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the Bone Recruiting
NCT03338790 Phase II Enzalutamide + Nivolumab Nivolumab + Rucaparib Docetaxel + Nivolumab An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer Recruiting
NCT03360721 Phase II Abiraterone + Apalutamide + Prednisone Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients Recruiting
NCT03361735 Phase II Leuprolide + Radium Ra 223 dichloride Goserelin + Radium Ra 223 dichloride Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer Recruiting
NCT03365791 Phase II LAG525 Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Active, not recruiting
NCT03371719 Phase II Apalutamide Radiation Therapy With or Without Apalutamide in Treating Patients With Stage III-IV Prostate Cancer Recruiting
NCT03385655 Phase II Savolitinib Darolutamide Adavosertib Prostate Cancer Biomarker Enrichment and Treatment Selection Recruiting
NCT03395197 Phase III Talazoparib Talazoparib + NHT vs. NHT Monotherapy in DDR+ mCRPC (TALAPRO-2) Recruiting
NCT03406858 Phase II Pembrolizumab Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Recruiting
NCT03412396 Phase II Apalutamide Single Arm Study of 6-Months Neoadjuvant ARN-509 Prior to Radical Prostatectomy Recruiting
NCT03413995 Phase II Rucaparib Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH) Recruiting
NCT03414034 Phase II Abiraterone + PCM-075 + Prednisone PCM-075 in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting
NCT03419234 Phase II Abiraterone + Prednisone Abiraterone + Cabazitaxel + Prednisone Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated With Docetaxel Recruiting
NCT03431350 Phase Ib/II JNJ-63723283 + Niraparib A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer Recruiting
NCT03432897 Phase II Olaparib BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes (337) Recruiting
NCT03436654 Phase II Abiraterone + Apalutamide + Prednisone A Study of Hormonal Therapy and Apalutamide With or Without Abiraterone Acetate and Prednisone in Newly Diagnosed Prostate Cancers Recruiting
NCT03437941 Phase Ib/II CORT125281 + Enzalutamide Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC Recruiting
NCT03442556 Phase II Carboplatin + Docetaxel + Rucaparib Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Recruiting
NCT03456804 Phase II CEP-11981 ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer Recruiting
NCT03465345 Phase I Metformin + OPC Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Withdrawn
NCT03480646 Phase Ib/II Enzalutamide Abiraterone + CPI-1205 + Prednisone CPI-1205 + Enzalutamide ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer Recruiting
NCT03503344 Phase II Apalutamide Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With Castration-Resistant Prostate Cancer (PILLAR) Not yet recruiting
NCT03511196 Phase I Abiraterone + Prednisone Leuprolide Goserelin Triptorelin Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Recruiting
NCT03516812 Phase II Olaparib + Testosterone Enanthate Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer Recruiting
NCT03532217 Phase I Ipilimumab + Nivolumab + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer Recruiting
NCT03533946 Phase II Rucaparib Rucaparib in Nonmetastatic prOstAte With BRCAness (ROAR) Recruiting
NCT03541928 Phase II Bicalutamide + HSV-Tk + Leuprolide + Valacyclovir Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery Recruiting
NCT03551782 Phase I Apalutamide + JNJ-63723283 A Study of JNJ-63723283, a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer Recruiting
NCT03554317 Phase II Nivolumab + Testosterone cypionate COMbination of Bipolar Androgen Therapy and Nivolumab Recruiting
NCT03556904 Phase II Abiraterone + Docetaxel + Enzalutamide FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE) Recruiting
NCT03565835 Phase II Abiraterone + Prednisone Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer Recruiting
NCT03570476 Phase II Olaparib Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer Recruiting
NCT03570619 Phase II Ipilimumab + Nivolumab Immunotherapy iImmunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT) Recruiting
NCT03572387 Phase II Azacitidine + Leuprolide + Tretinoin A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment Recruiting
NCT03577028 Phase I HPN424 Study of HPN424 in Patients With Advanced Prostate Cancer Recruiting
NCT03600350 Phase II Nivolumab + pTVG-HP plasmid DNA vaccine + Sargramostim pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer Recruiting
NCT03637543 Phase II Nivolumab Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer Recruiting
NCT03649841 Phase II Abiraterone + Prednisone Abiraterone + Prednisone + Radiotherapy Effects of Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Radiation on Prostate Cancer Not yet recruiting
NCT03678025 Phase III Docetaxel Nilutamide Triptorelin Bicalutamide Leuprolide Degarelix Goserelin Flutamide Prednisone Abiraterone Histrelin acetate Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Recruiting
NCT03686683 Phase III Sipuleucel-T Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (ProVent) Recruiting
NCT03690141 Phase II Tomivosertib A Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC) Recruiting
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Recruiting
NCT03706365 Phase II Abemaciclib + Abiraterone + Prednisone Abiraterone + Prednisone A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Recruiting
NCT03712930 Phase II Pamiparib Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency Recruiting
NCT03724747 Phase I BAY 2315497 Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Metastatic Castration Resistant Prostate Cancer Recruiting
NCT03725761 Phase II Sacituzumab govitecan IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy Recruiting
NCT03732820 Phase III Abiraterone Abiraterone + Olaparib Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer Recruiting
NCT03734653 Phase I Enzalutamide + Testosterone Testosterone Therapy in Castration Resistant Prostate Cancer Recruiting
NCT03748641 Phase III Abiraterone + Niraparib + Prednisone Abiraterone + Prednisone A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer Recruiting
NCT03753243 Phase II Enzalutamide + Pembrolizumab Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer Recruiting
NCT03767244 Phase III Apalutamide Abiraterone + Apalutamide Prednisone A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy Recruiting
NCT03770455 Phase II Darolutamide Avelumab + Enzalutamide Abiraterone + Avelumab Apalutamide Phase II Trial of Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC Recruiting
NCT03787680 Phase II AZD6738 + Olaparib Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) Not yet recruiting
NCT03805594 Phase I 177Lu-PSMA-617 + Pembrolizumab 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Not yet recruiting
NCT03809000 Phase II Goserelin Bicalutamide Enzalutamide Leuprolide A Trial to See What the Results Are for Radiation Therapy and Hormone Therapy vs Radiation Therapy With Enhanced Hormone Therapy With Enzalutamide for Patients With PSA Recurrence After Surgery (STEEL) Recruiting
NCT03821246 Phase II Atezolizumab + Emactuzumab Atezolizumab Atezolizumab + Enzalutamide Neoadjuvant Atezolizumab With or Without Enzalutamide in Localized Prostate Cancer Given Before Radical Prostatectomy Recruiting
NCT03821792 Phase II Abiraterone + Apalutamide + Prednisone Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer Not yet recruiting
NCT03827473 Phase II Abiraterone + Prednisone Docetaxel Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer (ACADEMIC) Recruiting
NCT03833921 Phase II Abiraterone + Prednisone Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer (APRE) Not yet recruiting
NCT03834506 Phase III Docetaxel + Prednisone Dexamethasone + Docetaxel + Pembrolizumab + Prednisone Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) Recruiting
NCT03834519 Phase III Abiraterone + Prednisone Enzalutamide Olaparib + Pembrolizumab Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010) Recruiting
NCT03840200 Phase Ib/II Ipatasertib + Rucaparib A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. Recruiting
NCT03861403 Phase Ib/II Avelumab + Cyclophosphamide + TRX518 A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors Recruiting
NCT03888612 Phase I ARV-110 A Phase 1 Clinical Trial of ARV-110 in Patients With Metastatic Castration-resistant Prostate Cancer. (mCRPC) Recruiting
NCT03899987 Phase II Aspirin + Rintatolimod Aspirin + Interferon alpha-2b + Rintatolimod Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery Not yet recruiting
NCT03902951 Phase II Abiraterone + Apalutamide + Leuprolide Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer Not yet recruiting
NCT03939689 Phase II Enzalutamide 131I-MIP-1095 + Enzalutamide Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW) Recruiting
NCT03964337 Phase II Cabozantinib Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (SPARC) Not yet recruiting
NCT03999515 Phase II Enzalutamide + Erdafitinib Abiraterone + Erdafitinib Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer Not yet recruiting